Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2019 Expert Video Report on Malignant Pleural Mesothelioma

Reporting from ESMO Congress 2019, Sanjay Popat comments on results from 3 studies presented in Malignant Pleural Mesothelioma. Considering the results, he thinks that we need to better identify the patients who may benefit from checkpoint inhibitors. In the relapse setting we have modest activity of 22% overall response rate, and to improve those results we should look at checkpoint inhibitors in the front line setting.

Abstracts:

  • LBA91: A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM) – results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
  • LBA92: Switch Maintenance Gemcitabine After First Line Chemotherapy In Patients With Malignant Mesothelioma; A Multicenter Open Label Phase II Trial (NVALT19)
  • 1841O: 2nd/3rd-line Nivolumab vs Nivo plus Ipilimumab in Malignant Pleural Mesothelioma: long-term results of IFCT-1501 MAPS2 phase 2R trial with a focus on hyperprogression (HPD)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings